Julia Lainster

Innovation thrives at the intersection of regulatory flexibility and robust oversight, especially within the dynamic field of first-in-class drugs. Today, we delve into this critical topic with Ivan Kairatov, a seasoned biopharma expert with extensive experience in research and development. With a

The rapid advancement of artificial intelligence (AI) has made significant strides in many sectors, and the realm of healthcare is no exception. Among the promising innovations is the use of AI-powered digital twins in clinical trials, particularly those targeting complex diseases like Amyotrophic

The healthcare industry is experiencing a substantial transformation with the advancement of telehealth, placing medical assistants at the forefront of adapting their roles to address new technological demands. This article explores the evolution of medical assistants' responsibilities in

Bayesian methods are revolutionizing the landscape of pediatric clinical trial design by offering flexibility, precision, and ethical considerations that are crucial when dealing with vulnerable populations. These approaches are particularly suited to the unique challenges of pediatric trials,

Schrödinger, a well-established player in the computational chemistry and drug discovery space, has recently made headlines by embracing artificial intelligence (AI). The company’s CEO, Ramy Farid, officially announced this strategic pivot during the presentation of the company's year-end re

The hospice industry faces significant regulatory challenges that have become more pronounced in recent years, with key concerns including evolving telehealth policies and program integrity issues. These challenges were highlighted by hospice professionals in the 2025 Outlook Survey conducted by

Breast cancer survivors are growing in number, thanks to early detection and effective treatments. However, alongside their survival, an undercurrent of accelerated aging has been observed, raising questions about the long-term impacts of the disease and its treatments on biological aging. This

Immunovant, a biotechnology company known for its innovative treatments for autoimmune diseases, has recently announced a significant shift in its development strategy. Despite late-stage successes with its experimental drug batoclimab, the company has decided to momentarily hold back on seeking

Ivan Kairatov is a Biopharma expert with deep knowledge of tech and innovation in the industry and experience in research and development. Today, we are discussing Med-Life Discoveries (MLD), their mission, and the promising results of their Phase I study on PPI-1011, a synthetic plasmalogen

Clinical trials have long been criticized for their lack of diversity, particularly in the participation of women. Historically, such exclusions have led to significant gaps in medical knowledge and treatment efficacy across genders, resulting in potentially biased outcomes for a substantial